Funding round
Enveda Series A
Enveda, which works in drug discovery and development in Boulder, raised $51M in a Series A round announced on 22 Jun 2021, led by Lux Capital. 9 firms took part, 4 of them already investors. It is Enveda's second venture round on record; the one before was a Seed in Dec 2020.
$51M
Amount raised
Not disclosed
Post-money valuation
9
Investors
1 lead
Valuation
What this round says about the price
Enveda did not disclose a valuation in this round. It came 6 months after Enveda's Seed. It is 7.1% of the $715M Enveda has raised in the venture rounds on record. Enveda raised again 18 months later: a Series B round of $68M in Dec 2022. Its next priced round, a Series E in Sep 2026, valued it at $2.00B.
Enveda's funding rounds
Enveda has 6 venture rounds on record. This one is highlighted.
- Seed 27 Dec 2020, led by True Ventures $4.9M
- Series A this round 22 Jun 2021, led by Lux Capital $51M
- Series B 21 Dec 2022, led by Dimension $68M
- Series C 21 Nov 2024, led by Kinnevik and FPV Ventures $130M
- Series D 4 Sep 2025, led by Premji Invest $150M
- Series E 23 Sep 2026, led by Catalio Capital Management $311M$2.00B post-money
Investors
Who put money in
Lux Capital led the round with 8 other firms. True Ventures, Wireframe Ventures, Village Global and Recursion had backed Enveda before.
Lead investor
- Lux Capital backs 194 venture-backed companies new investor
Also in the round
- Two Sigma Ventures backs 60 venture-backed companies new investor
- backs 42 venture-backed companies new investor
- backs 57 venture-backed companies new investor
- backs 16 venture-backed companies new investor
- backs 158 venture-backed companies existing investor
- backs 24 venture-backed companies existing investor
- backs 120 venture-backed companies existing investor
- Recursion existing investor
Use of proceeds
What the money is for
According to the announcement, the money goes to hiring, product development, scaling operations and working capital.
- Hiring
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
212 Series A rounds in Biotechnology within a year either side disclosed an amount; the median was $30M, and this round was 1.7 times the median. The closest in time, other companies' Series A rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 3 Jun 2021 | $63M | not disclosed | Versant Ventures |
| Biotechnology | 7 Jun 2021 | $47M | not disclosed | Mirae Asset Capital and Celltrion |
| Biotechnology | 22 Jun 2021 | $24M | not disclosed | Newton Biocapital |
| Biotechnology | 18 Jun 2021 | $24M | not disclosed | EVX Ventures and Boehringer Ingelheim Venture Fund |
| Biotechnology | 17 Jun 2021 | $12M | not disclosed | Keiretsu Forum |
| Biotechnology | 1 Jun 2021 | $10M | not disclosed | not named |
| Biotechnology | 18 Jun 2021 | $6.4M | not disclosed | not named |
| Biotechnology | 1 Jun 2021 | $5.9M | not disclosed | not named |
Sources
Where this comes from
Reported by 3 sources.
Questions
Frequently asked
How much did Enveda raise in its Series A round?
Enveda raised $51M in its Series A round, announced in Jun 2021.
Who led Enveda's Series A round?
Lux Capital led it, with Two Sigma Ventures, Hummingbird VC, Catalio Capital Management, Lifeforce Capital and True Ventures and 3 more.
What was Enveda's valuation at the Series A round?
It was not disclosed.
How does it compare with other Series A rounds in Biotechnology?
212 Series A rounds in Biotechnology within a year either side disclosed an amount; the median was $30M, and this round was 1.7 times the median.
Did Enveda raise again after this round?
Yes: a Series B round in Dec 2022 of $68M.